| Literature DB >> 15245594 |
Yusuke Oji1, Shoji Nakamori, Masahiro Fujikawa, Shin-Ichi Nakatsuka, Asumi Yokota, Naoya Tatsumi, Sakie Abeno, Ai Ikeba, Satoshi Takashima, Masanori Tsujie, Hirofumi Yamamoto, Masato Sakon, Riichiro Nezu, Kiyoshi Kawano, Sumiyuki Nishida, Kazuhiro Ikegame, Manabu Kawakami, Akihiro Tsuboi, Yoshihiro Oka, Kiyoshi Yoshikawa, Katsuyuki Aozasa, Morito Monden, Haruo Sugiyama.
Abstract
The expression of the Wilms' tumor gene WT1 was examined by immunohistochemistry in 40 cases of pancreatic ductal adenocarcinoma. WT1 protein was expressed in 30 (75%) of the 40 pancreatic ductal adenocarcinomas, but not in the remaining 10 (25%). In normal pancreatic ductal cells, WT1 protein was undetectable. No correlations between WT1 expression and clinicopathological parameters such as age, sex, T or N stage, tumor location, and tumor differentiation were observed. Treatment with WT1 antisense oligomers significantly inhibited the growth of five human pancreatic cancer cell lines, PSN1, MiaPaCa2, ASPC1, BxPC3, and PCI6, expressing the WT1 gene. These results indicate an important role of the WT1 gene in the tumorigenesis of pancreatic ductal adenocarcinoma expressing WT1 and provide a rationale for new treatment strategies to treat pancreatic ductal adenocarcinoma by targeting the WT1 gene and its product.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15245594 DOI： 10.1111/j.1349-7006.2004.tb02490.x
Source DB: PubMed Journal: Cancer Sci ISSN： 1347-9032 Impact factor: 6.716